ONO PHARMA USA, INC. was established in 1998 as the US subsidiary of ONO PHARMACEUTICAL CO., LTD. (ONO), headquartered in Osaka, Japan. ONO is an R&D-oriented pharmaceutical company specializing in the discovery and development of prescription drugs. ONO’s history dates back more than 300 years and we have consistently succeeded in bringing patients "first in class" medicines, such as OPDIVO® (nivolumab).

Committed to our corporate philosophy, "Dedicated to the Fight against Disease and Pain," we aim to establish ourselves as a global, R&D-based pharmaceutical company (Global Specialty Pharma) that discovers innovative drugs to treat patients around the world. Consistent with this vision, ONO identified oncology, immunology, neurology, and specialty domains as priority areas of research. Within these domains, we take advantage of current technologies and expertise to maintain our vigorous pursuit of novel therapies and prioritize areas of unmet medical need.

To improve our drug discovery capabilities, we promote strategic partnerships globally, and work to obtain groundbreaking drug discovery seeds and world-class advanced technologies. We work with biopharmaceutical companies, universities and other research institutions in the US and Europe and consistently execute licensing activities to expand our development pipeline. Further, we continue to strengthen our environmental, social and governance (ESG) initiatives to add value to society through our business activities and to develop and launch drugs that truly benefit patients, thereby solidifying ONO’s reputation as well as increasing our social value and competitiveness in the global market.

On behalf of ONO, we would like to thank you for your continued support.